Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Olmesartan Medoxomil 40 mg in Healthy Adults
NCT03951051Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of olmesartan in hypertension (HTN) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration (Cmax) at 48 hours and Area Under the Curve to Last Timepoint (AUC0-t). Started May 2019; status: completed.
02
Drugs
olmesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03951051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951051.